Latest Icon Plc (ICLR) Headlines
Why ICON Public (ICLR) Could Be an Impressive Growth Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:41AM CDT
ICON Public Limited saw EPS growth of 77.0% last year, and is looking great for this year too
17.9% Return Seen to Date on SmarTrend ICON Call (ICLR)
Comtex SmarTrend(R) - Mon Mar 10, 10:00AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 17.94% as of today's recent price of $46.84.
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Is ICON Public Limited Company (ICLR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:59AM CDT
ICON Public Limited Company might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Informatica Helps ICON Improve Clinical Trials Management System
GlobeNewswire - Thu Mar 06, 6:08AM CST
Informatica Corporation (Nasdaq:INFA), the world's number one independent provider of data integration software, today announced that ICON plc is improving the company's clinical trials and development process with Informatica. By standardizing on a best-in-class, multidomain Informatica MDM solution, this global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries is creating a consolidated and reliable view of business-critical data -- such as investigators and sites -- and the relationships between the data. This strategy is unleashing the potential of ICON's data: unlocking faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting.
MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
ICON Up 16.7% Since SmarTrend Uptrend Call (ICLR)
Comtex SmarTrend(R) - Mon Mar 03, 9:24AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 16.66% as of today's recent price of $46.33.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
Express Scripts Reports In-Line Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:00AM CST
Express Scripts posted fourth quarter 2013 earnings per share (excluding special items) of $1.12, up from $1.05 reported in the year-ago quarter and in line with the Zacks Consensus Estimate
3M to Acquire Treo Solutions
Business Wire - Fri Feb 21, 8:00AM CST
3M announced today that it has entered into an agreement to acquire Treo Solutions, a leading provider of data analytics and business intelligence to healthcare payers and providers. Terms of the transaction were not disclosed.
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% year on year. Full Year 2013 Revenue was $1.34 billion, up 20% year on year, EPS was $1.77 up 77% year on year. Guidance issued for 2014.
Business Wire - Thu Feb 20, 5:00AM CST
--Quarter 4 net revenue increased 15% year on year to $345 million. Full Year 2013 net revenue increased 20% to $1.34 billion.
ICON Announces Appointment of Ms. Mary Pendergast to Board of Directors
Business Wire - Thu Feb 20, 5:00AM CST
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Ms. Mary Pendergast, J.D., LL.M., as a non-executive director.
Shares of ICLR Up 12.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 14, 11:18AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 12.83% as of today's recent price of $44.81.
Charles River Beats Earnings Estimates in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 9:15AM CST
Charles River Labs reported 4Q13 earnings (excluding special items) of 73 cents per share, beating the Zacks Consensus Estimate of 68 cents
ICON Has Returned 11.6% Since SmarTrend Recommendation (ICLR)
Comtex SmarTrend(R) - Fri Feb 07, 10:02AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 1 month, ICON has returned 11.65% as of today's recent price of $44.34.
2 Stocks Rising on Unusual Volume
at The Street - Thu Feb 06, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Stock Market Closes Lower But Well Off Session Lows
at Investor's Business Daily - Wed Feb 05, 3:15PM CST
The stock market today closed lower after trimming most of the morning losses. The Nasdaq, which was off nearly 1.6% in early trading, closed 0.5% lower. The S&P 500 shed 0.2% and the Dow Jones industrial average less than 0.1%. Volume was mildly...
Why ICON Public (ICLR) Could Be an Impressive Growth Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:41AM CDT
ICON Public Limited saw EPS growth of 77.0% last year, and is looking great for this year too
17.9% Return Seen to Date on SmarTrend ICON Call (ICLR)
Comtex SmarTrend(R) - Mon Mar 10, 10:00AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 17.94% as of today's recent price of $46.84.
Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019
M2 - Mon Mar 10, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh67xx/life_sciences_bpo) has announced the addition of the "Global Life Sciences BPO Market Market Forecasts & Opportunities, 2019" report to their offering. The life sciences BPO market comprises services offered by Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) to the biotech pharmaceutical companies. A rise in demand for low cost drugs, patent expirations and uncertain economic conditions have compelled the pharmaceutical players to take support of various outsourcing services. This support has facilitated pharma players to streamline their value chain and focus more on its core strategies. Pharmaceutical companies are now forming long term partnership with the CROs and CMOs to share the costs involved in drug discovery to post marketing approvals. Moreover, they are also leveraging CROs and CMOs expertise such as use of novel technologies, trained staff and previous experiences for effective outcomes. The research report on life sciences BPO provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of life sciences BPO on the basis of different CRO and CMO services. The CRO services comprises clinical data management, monitoring, medical writing, regulatory services, pharmacovigilance, bio-statistics, drug discovery and pre-clinical tests. The CMO services include API manufacturing, Finished Dosage Formulation development and manufacturing and Packaging. The global life sciences BPO market has been segmented based on all the above- mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in terms of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global life sciences BPO market.The section also covers opportunities, market attractiveness analysis and Porter's Five Forces analysis for the market participants. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Life Sciences BPO Market Dynamics Chapter 4 Global Life Sciences BPO Market, by Segments Chapter 5 Global Life Sciences BPO Market, by Geography Chapter 6 Global Life Sciences BPO Market Share Analysis Chapter 7 Recommendations Chapter 8 Company Profiles - Accenture, Plc - Boehringer Ingelheim GmbH - Catalent Pharma Solutions, Inc. - Charles River Laboratories International, Inc. (CRL) - Cognizant Technology Solutions - Covance, Inc. - DSM - Fareva - ICON, Plc - Infosys - International Business Machines Corporation - Lonza Group - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Parexel International Corporation - Patheon, Inc. - Piramal Healthcare - PRA International, Inc. - Quintiles Transnational Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/gh...iences_bpo
Is ICON Public Limited Company (ICLR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:59AM CDT
ICON Public Limited Company might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Informatica Helps ICON Improve Clinical Trials Management System
GlobeNewswire - Thu Mar 06, 6:08AM CST
Informatica Corporation (Nasdaq:INFA), the world's number one independent provider of data integration software, today announced that ICON plc is improving the company's clinical trials and development process with Informatica. By standardizing on a best-in-class, multidomain Informatica MDM solution, this global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries is creating a consolidated and reliable view of business-critical data -- such as investigators and sites -- and the relationships between the data. This strategy is unleashing the potential of ICON's data: unlocking faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting.
MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
ICON Up 16.7% Since SmarTrend Uptrend Call (ICLR)
Comtex SmarTrend(R) - Mon Mar 03, 9:24AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 16.66% as of today's recent price of $46.33.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
Express Scripts Reports In-Line Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:00AM CST
Express Scripts posted fourth quarter 2013 earnings per share (excluding special items) of $1.12, up from $1.05 reported in the year-ago quarter and in line with the Zacks Consensus Estimate
3M to Acquire Treo Solutions
Business Wire - Fri Feb 21, 8:00AM CST
3M announced today that it has entered into an agreement to acquire Treo Solutions, a leading provider of data analytics and business intelligence to healthcare payers and providers. Terms of the transaction were not disclosed.
Omnicare (OCR) Falls: Stock Goes Down 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:37AM CST
Omnicare Inc. (OCR) saw a big move last session. This stock, trading at a volatile range of $60.68–$64.54 in the past one-month time frame, showed a sharp decline yesterday at $60.98.
ICON Reports Fourth Quarter 2013 Revenue of $345 million, up 15% year on year and EPS of 53c, up 56% year on year. Full Year 2013 Revenue was $1.34 billion, up 20% year on year, EPS was $1.77 up 77% year on year. Guidance issued for 2014.
Business Wire - Thu Feb 20, 5:00AM CST
--Quarter 4 net revenue increased 15% year on year to $345 million. Full Year 2013 net revenue increased 20% to $1.34 billion.
ICON Announces Appointment of Ms. Mary Pendergast to Board of Directors
Business Wire - Thu Feb 20, 5:00AM CST
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Ms. Mary Pendergast, J.D., LL.M., as a non-executive director.
Shares of ICLR Up 12.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 14, 11:18AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 2 months, ICON has returned 12.83% as of today's recent price of $44.81.
Charles River Beats Earnings Estimates in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 9:15AM CST
Charles River Labs reported 4Q13 earnings (excluding special items) of 73 cents per share, beating the Zacks Consensus Estimate of 68 cents
ICON Has Returned 11.6% Since SmarTrend Recommendation (ICLR)
Comtex SmarTrend(R) - Fri Feb 07, 10:02AM CST
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on December 26th, 2013 at $39.72. In approximately 1 month, ICON has returned 11.65% as of today's recent price of $44.34.
2 Stocks Rising on Unusual Volume
at The Street - Thu Feb 06, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Stock Market Closes Lower But Well Off Session Lows
at Investor's Business Daily - Wed Feb 05, 3:15PM CST
The stock market today closed lower after trimming most of the morning losses. The Nasdaq, which was off nearly 1.6% in early trading, closed 0.5% lower. The S&P 500 shed 0.2% and the Dow Jones industrial average less than 0.1%. Volume was mildly...
